US 9918968
Rapamycin analogs targeting proteasome function in the treatment of cancer
granted A61KA61K31/436A61K31/453
Quick answer
US patent 9918968 (Rapamycin analogs targeting proteasome function in the treatment of cancer) held by The Board of Regents of the University of Texas System expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Mar 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 31
- CPC classes
- A61K, A61K31/436, A61K31/453, A61K31/69, A61K45/06